Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril

Journal of the American College of Cardiology

Volumn 34, Issue 1, 1999, Pages 170-176

  Katz, Stuart D ^a   Radin, Michael ^b   Graves, Thomas ^b   Hauck, Cynthia ^b   Block, Alan ^b   LeJemtel, Thierry H ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Medicine ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IFETROBAN; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EXERCISE; FEMALE; FOREARM BLOOD FLOW; HAND GRIP; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE BLOOD FLOW; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

AGED; ASPIRIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENALAPRIL; FEMALE; FOREARM; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OXAZOLES; PLATELET AGGREGATION INHIBITORS; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0033165566     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00180-1     Document Type: Article

References (34)

1. Cody R.J. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction (review). Arch Intern Med. 154:1994;2029-2036.
2. Antiplatelet Trialist's Collaboration . Collaborative overview of randomised trials of antiplatelet therapy - I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients . BMJ. 308:1994;81-106.
3. Cleland J.G., Bulpitt C.J., Falk R.H., et al. Is aspirin safe for patients with heart failure? (review, 53 refs) Br Heart J. 74:1995;215-219.
4. Vanhoutte P.M., Auch-schwelk W., Biondi M.L., et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 28:1989;95S-104S.
5. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 308:1983;800-805.
6. Hall D., Zeitler H., Rudolph W. Counteraction of the vadodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 20:1994;1549-1555.
7. Massie B.M., Kramer B.L., Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 69:1984;1135-1141.
8. Mancini D.M., Davis L., Wexler J.P., et al. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. J Am Coll Cardiol. 10:1987;845-850.
9. Koller A., Sun D., Kaley G. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res. 72:1993;1276-1284.
10. Wennmalm A. Participation of prostaglandins in the regulation of peripheral resistance. Oates J.A., Prostaglandins and the Cardiovascular System. 1982;303-331 Raven Press, New York.
11. Greenfield A.D.M., Whitney R.J., Mowbray J.F. Methods for the investigation of peripheral blood flow. Br Med Bull. 19:1963;101-109.
12. Longhurst J., Capone R.J., Mason D.T., Zelis R. Comparison of blood flow measured by plethysmograph and flowmeter during steady state forearm exercise. Circulation. 49:1974;535-540.
13. Schumacher W.A., Steinbacher T.E., Youssef S., Ogletree M.L. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 44:1992;389-397.
14. Ogletree M.L., Harris D.A., Schumacher W.A., et al. Pharmacological profile of BMS 180,291 a potent orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist . J Pharmacol Exp Ther. 262:1993;570-578.
15. Gimbrone M.A.J., Alexander R.W. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science. 189:1975;219-220.
16. Blumberg A.L., Denny S.E., Marshall G.R., Needleman P. Blood vessel-hormone interaction angiotensin, bradykinin, and prostaglandins . Am J Physiol. 232:1977;H305-H310.
17. Galler M., Backenroth R., Folkert V.W., Schlondorff D. Effect of converting enzyme inhibitors on prostaglandin synthesis by isolate glomeruli and aortic strips from rats. J Pharmacol Exp Ther. 220:1982;23-28.
18. Dzau V.J., Packer M., Lilly L.S., et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 310:1984;347-352.
19. Katz S.D., Schwarz M., Yuen J., LeJemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation. 88:1993;55-61.
20. Wang J., Seyedi N., Xiao-Bin X., et al. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol. 266:1994;H670-H680.
21. Nishimura H., Kubo S., Ueyama M., et al. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J. 117:1989;100-105.
22. van Wijngaarden J., Smit A.J., de Graeff P.A., et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 23:1994;240-245.
23. Townend J.N., Doran J., Lote C.J., Davies M.K. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J. 73:1995;434-441.
24. Drexler H., Banhardt U., Meinertz T., et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. Circulation. 79:1989;491-502.
25. Pflugfelder P.W., Baird M.G., Tonkon M.J., et al. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators . J Am Coll Cardiol. 22:1993;1557-1563.
26. Zelis R., Sinoway L.I., Leuenberger U., et al. Time-constant adaptations in heart failure. Eur Heart J. 12:(Suppl C):1991;2-7.
27. Koller A., Kaley G. Prostaglandins mediate arteriole dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res. 67:1990;529-534.
28. Young E.W., Sparks H.V. Prostaglandins and exercise hyperemia of dog skeletal muscle. Am J Physiol. 238:1980;H190-H195.
29. Böger R.H., Bode-Böger S.M., Schröder E.P., et al. Increased prostacyclin production during exercise in untrained and trained men effect of low-dose aspirin . J Appl Physiol. 78:1995;1832-1838.
30. Wilson J.R., Kapoor S.C. Contribution of prostaglandins to exercise-induced vasodilation in humans. Am J Physiol. 265:1993;H171-H175.
31. Shoemaker J.K., Naylor H.L., Pozeg Z.I., Hughson R.L. Failure of prostaglandins to modulate the time course of blood flow during dynamic forearm exercise in humans. J Appl Physiol. 81:1996;1516-1521.
32. Rowell L.B. Human Cardiovascular Control. 1993;255-301 Oxford University Press, New York.
33. Baur L.H.B., Schipperheyn J.J., van der Laarse A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 73:1995;227-236.
34. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 79:1997;115-119.